December 28, 2014 9:37 PM ET

Pharmaceuticals

Company Overview of Constellation Pharmaceuticals, Inc.

Company Overview

Constellation Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops drugs in the field of epigenetics. The company develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its drug discovery and development platform creates a pipeline of programs across the writer, eraser, and reader classes of epigenetic targets to develop new drugs in oncology, inflammation, and other therapeutic areas. Constellation Pharmaceuticals, Inc. has a strategic agreement with Genentech. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in April 2008. Constellation Phar...

215 First Street

Suite 200

Cambridge, MA 02142

United States

Founded in 2008

Phone:

617-714-0555

Fax:

617-661-5382

Key Executives for Constellation Pharmaceuticals, Inc.

Chief Executive Officer and President
Executive Chairman
Age: 52
Founder
Compensation as of Fiscal Year 2014.

Constellation Pharmaceuticals, Inc. Key Developments

Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM

Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Joe Collard, Co-Founder and CEO.

Constellation Pharmaceuticals, Inc. Announces New Preclinical Data on Novel Bet Bromodomain Inhibitors

Constellation Pharmaceuticals, Inc. announced the publication of a study in the Journal of Experimental Medicine demonstrating that small molecule inhibitors selectively targeting BET bromodomains can suppress T helper 17 (T 17) differentiation and T 17-mediated pathology in models of autoimmune diseases. The paper appears in the online early edition of J Exp Med published on October 7, 2013. During the last decade, researchers have uncovered the importance of T 17 cells as an integral part of the immune system that protects the human body from infections. However, this research has also shown that, when pathologically activated, these cells can attack multiple organs in the body and trigger autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Because of the important roles that T 17 cells play in both normal and dysregulated immune function, many academic, biotech and pharmaceutical laboratories have research programs devoted to targeting T 17 cells.

Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM

Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM. Venue: Four Seasons Hotel, San Francisco, California, United States. Speakers: Keith E. Dionne, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Artesian Therapeutics, Inc. United States
Vivelle Ventures LLC United States
IVAX Pharmaceuticals, Inc. United States
Phytoceutica, Inc. United States
DexGen Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 5, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Constellation Pharmaceuticals, Inc., please visit www.constellationpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.